HC Wainwright Analysts Decrease Earnings Estimates for SAGE

Sage Therapeutics, Inc. (NASDAQ:SAGE) – Stock analysts at HC Wainwright decreased their FY2024 earnings estimates for shares of Sage Therapeutics in a research report issued to clients and investors on Wednesday, October 30th. HC Wainwright analyst D. Tsao now expects that the biopharmaceutical company will post earnings per share of ($6.72) for the year, down from their prior estimate of ($6.58). HC Wainwright has a “Neutral” rating and a $14.00 price target on the stock. The consensus estimate for Sage Therapeutics’ current full-year earnings is ($6.43) per share. HC Wainwright also issued estimates for Sage Therapeutics’ Q4 2024 earnings at ($1.69) EPS, Q1 2025 earnings at ($1.54) EPS, Q2 2025 earnings at ($1.30) EPS, Q3 2025 earnings at ($0.99) EPS, Q4 2025 earnings at ($0.95) EPS, FY2025 earnings at ($4.78) EPS, FY2026 earnings at ($3.63) EPS and FY2027 earnings at ($2.87) EPS.

SAGE has been the topic of a number of other reports. Mizuho reduced their price target on shares of Sage Therapeutics from $18.00 to $16.00 and set a “neutral” rating on the stock in a research report on Friday, July 19th. Robert W. Baird dropped their price objective on shares of Sage Therapeutics from $13.00 to $9.00 and set a “neutral” rating on the stock in a report on Wednesday, October 9th. Oppenheimer lowered their target price on shares of Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating on the stock in a research note on Wednesday. TD Cowen cut shares of Sage Therapeutics from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $16.00 to $10.00 in a research note on Tuesday, July 30th. Finally, Wedbush lowered their price objective on shares of Sage Therapeutics from $9.00 to $8.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 9th. Three analysts have rated the stock with a sell rating, seventeen have given a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, Sage Therapeutics has a consensus rating of “Hold” and a consensus target price of $12.89.

Sage Therapeutics Price Performance

NASDAQ SAGE opened at $6.05 on Friday. Sage Therapeutics has a 12 month low of $5.84 and a 12 month high of $28.26. The company has a market capitalization of $370.10 million, a price-to-earnings ratio of -1.08 and a beta of 0.91. The company’s fifty day moving average price is $7.44 and its two-hundred day moving average price is $9.95.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.52) by ($0.01). Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%. The firm had revenue of $11.87 million for the quarter, compared to analyst estimates of $10.80 million. During the same period in the previous year, the business posted ($2.81) earnings per share. Sage Therapeutics’s revenue for the quarter was up 337.1% on a year-over-year basis.

Institutional Trading of Sage Therapeutics

Large investors have recently bought and sold shares of the business. Headlands Technologies LLC boosted its position in Sage Therapeutics by 245.3% during the 2nd quarter. Headlands Technologies LLC now owns 3,916 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 2,782 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Sage Therapeutics by 66.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company’s stock valued at $85,000 after acquiring an additional 4,672 shares during the period. Creative Planning bought a new stake in Sage Therapeutics in the 3rd quarter valued at $88,000. Lazard Asset Management LLC bought a new stake in Sage Therapeutics in the 1st quarter valued at $127,000. Finally, Quest Partners LLC increased its position in Sage Therapeutics by 14.5% during the 2nd quarter. Quest Partners LLC now owns 11,763 shares of the biopharmaceutical company’s stock worth $128,000 after buying an additional 1,486 shares during the period. 99.22% of the stock is owned by institutional investors.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.